The distribution characteristics, antibiotic resistance patterns of Klebsiella pneumoniae at the 108 Military Central Hospital (2-4/2024)
Main Article Content
Abstract
Klebsiella pneumoniae is a common cause of infections in hospitals and communities, ranging from mild to severe. Currently, K. pneumoniae is becoming a public health concern due to its pathogenicity and resistance to many antibiotics, posing a significant challenge in clinical treatment and disease prevention. A cross-sectional descriptive study was conducted on 163 Klebsiella pneumoniae isolates obtained from clinical specimens of patients at the 108 Military Central Hospital. The objective of the study was to describe the distribution characteristics and antibiotic resistance patterns of Klebsiella pneumoniae isolated at the 108 Military Central Hospital from February to April 2024. The results showed that K. pneumoniae was mainly isolated from male patients (74.2%), over 60 years old (70%) and treated in internal medicine (81%). The bacteria were isolated from many different specimens, the most common of which was respiratory tract secretions. The results of the antibiotic susceptibility test showed that K. pneumoniae was more than 50% resistant to 13/14 tested antibiotics, of which the resistance rate to the aminoglycoside group was the lowest (amikacin: 39.5%; gentamicin 48.1%). There were 77 carbapenem-resistant strains (accounting for 47.2%) with minimum inhibitory concentration (MIC) values determined with two antibiotics, ceftazidime/avibactam and colistin. With a threshold value of MIC ≥ 4 µg/ml, K. pneumoniae strains had a resistance rate of colistin of 14.3%. Meanwhile, only 31.2% of strains had MIC with ceftazidime/avibactam ≤ 8 µg/ml, reaching the sensitivity level according to CLSI 2023 classification.
Article Details
Keywords
K. pneumoniae, colistin, ceftazidime/avibactam, kháng kháng sinh
References
2. Li W, Sun G, Yu Y, et al. Increasing occurrence of antimicrobial-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae isolates in China. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014; 58(2): 225-232. doi:10.1093/cid/cit675.
3. Centers for Disease Control and Prevention (U.S.). Antibiotic Resistance Threats in the United States, 2019. Centers for Disease Control and Prevention (U.S.); 2019. doi:10.15620/cdc:82532.
4. Alvarez-Uria G, Gandra S, Mandal S, Laxminarayan R. Global forecast of antimicrobial resistance in invasive isolates of Escherichia coli and Klebsiella pneumoniae. Int J Infect Dis. 2018; 68: 50. doi:10.1016/j.ijid.2018.01.011.
5. Bộ Y Tế. Báo cáo giám sát kháng kháng sinh tại Việt Nam 2020. 2023
6. Đỗ Thị Tuyết Chinh, Văn Đình Tráng và cộng sự. Thực trạng kháng kháng sinh của Klebsiella pneumoniae phân lập tại Bệnh Viện Bệnh Nhiệt Đới Trung Ương năm 2022. Tạp chí Truyền nhiễm Việt Nam. 2023; 3(43): 32-38. doi:10.59873/vjid.v3i43.304.
7. Durdu B, Koc MM, Hakyemez IN, et al. Risk Factors Affecting Patterns of Antibiotic Resistance and Treatment Efficacy in Extreme Drug Resistance in Intensive Care Unit-Acquired Klebsiella Pneumoniae Infections: A 5-Year Analysis. Med Sci Monit Int Med J Exp Clin Res. 2019; 25: 174. doi:10.12659/MSM.911338.
8. Nguyễn Khắc Tiệp, Thâm Thị Dung Nhi, Phạm Hồng Nhung. Mức độ đề kháng và tỉ lệ vi khuẩn dai dẳng với colistin của các chủng Klebsiella pneumoniae. Tạp chí Nghiên cứu Y học. 2024; 178(5): 9-16. doi:10.52852/tcncyh.v178i5.2359.
9. Liu Y, Lin Y, Wang Z, et al. Molecular Mechanisms of Colistin Resistance in Klebsiella pneumoniae in a Tertiary Care Teaching Hospital. Front Cell Infect Microbiol. 2021; 11. doi:10.3389/fcimb.2021.673503.
10. Uzairue LI, Rabaan AA, Adewumi FA, et al. Global Prevalence of Colistin Resistance in Klebsiella pneumoniae from Bloodstream Infection: A Systematic Review and Meta-Analysis. Pathogens. 2022; 11(10): 1092. doi:10.3390/pathogens11101092.
11. Yang X, Wang D, Zhou Q, et al. Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam. BMC Microbiol. 2019; 19(1): 240. doi:10.1186/s12866-019-1613-5.